Erbitux cetuximab: Additional Phase III data

Additional data from the Phase III EPIC study in about 1,300 patients showed that "extensive post-trial use of Erbitux" by patients in the irinotecan arm may explain the lack of

Read the full 307 word article

How to gain access

Continue reading with a
two-week free trial.